TEV-56278

TEV-56278 is a novel human antibody-cytokine fusion protein developed by Teva Pharmaceutical Industries for the treatment of solid tumors. The drug consists of an antibody targeting Programmed cell death protein 1 (PD-1) fused to an attenuated interleukin-2 (IL-2) cytokine, designed to selectively deliver IL-2 to PD-1 positive T cells. This targeted delivery aims to amplify anti-tumor T-cell activity while minimizing systemic toxicities associated with non-selective IL-2 exposure. Unlike traditional PD-1 blocking antibodies, TEV-56278 binds the PD-1 receptor without blocking ligand binding or competing with existing anti-PD-(L)1 therapies, allowing for potential combination use. Preclinical studies have demonstrated that TEV-56278 can promote tumor regression and establish durable antitumor immunity in murine models by reprogramming the tumor microenvironment and enhancing tumor-infiltrating T cell responses. The drug is currently being evaluated in phase 1 clinical trials as both monotherapy and in combination with pembrolizumab for patients with advanced or metastatic solid tumors who are resistant or intolerant to standard therapies[1][2][3][4][5][6].

Other names

TEV 56278TEV56278TEV-56278